Renewing breath
Restoring lives
Dual innovation, one goal:
revolutionizing cystic fibrosis care
where current therapies fall short
Cystic Fibrosis, challenges and unmet needs !
Incurable, cystic fibrosis (CF or Mucoviscidose in french) is a devastating disease, with a growing number of people diagnosed worldwide.
Although modulator therapies exist to target some of these mutations, significant gaps remain in patient care.
110 000 persons
diagnosed around the world in 2023
18 % untreated
no therapeutic solution
up to 80 % patients
with a severe class II mutation (p.Phe508del)
Why ?
Untargeted mutations
10-15%
Partial responses
20-30%
Unbearable costs
A breakthrough with the novel cystic fibrosis bitherapy developed by Aceso Therapeutics
Developed through years of academic research and collaboration, our scalable platform – protected by three first-in-class molecule patents – targets unmet therapeutics needs in respiratory diseases. Advance development now propels our cystic fibrosis dual therapy program forward.
Cystic fibrosis is a rare genetic disease caused by a mutation in the CFTR gene (Cystic fibrosis transmembrane conductance regulator), which codes for a protein that regulates ion transport across cells. This defect makes secretions like mucus thick and sticky, mainly affecting the lungs and the digestive system.
Our team is currently developing a novel bitherapy approach that shows strong potential to significantly improve clinical outcomes for cystic fibrosis patients, by targeting the main mutations of CFTR gene with 2 “first in class” molecules.
A combinaison with a unique mechanism of action to improve CFTR ion channel activity, essential to restore the normal hydration for for effective mucociliary clearance. Thus helping to improve and preserve lung function, which is primarily affected in cystic fibrosis.
We believe this dual strategy has the potential to address critical unmet needs where existing therapies fall short. Fully focused on advancing toward preclinical regulatory milestones, our objective is to enable IND submission and initiate clinical trials.
No toxicity
demonstrated in epithelium from CF patients and mice
Better CFTR activity
demonstrated in epithelium from CF patients
Renewing breath. Restoring lives
Despite the success of current CFTR modulators, many cystic fibrosis patients remain underserved, due to untargeted mutations, partial responses, or prohibitive costs.
We are changing that with our breakthrough bitherapy under the development for the future clinical trials.
Why invest ?
Untapped Market Opportunity
7B+ market potential estimated as the first solution for 30% of CF patients remaning underserved.
Validated Scientific Proof
Prove of concept validated in epithelium from CF patients with strong data and solid exclusive IP protection.
Accelerated Regulatory Path
Fast-track pathway due to orphan drug designation and clear unmet need.
Aceso Therapeutics
Aceso Therapeutics is a biotech company founded by an experienced international entrepreneur in collaboration with the scientists behind its core innovations.
We specialize in developing first-in-class molecules aimed at creating the next generation of innovative treatments. Our approach is driven by a scalable, patent-protected technology platform built on three proprietary patents.
Our mission is to create value by improving patient care, maximizing returns for our investors, and making a positive, lasting impact on the socio-economic and environmental ecosystem.
Team
Thomas Tran, MBA
Co-Founder, CEO
Entrepreneur, Executive leader in the medical and the chemistry analytical.
Magali Taulan – Cadars, PhD
Co-Founder, CSO
Researcher director, expert in genetic and rare diseases
Prisca Boisguerin, PhD
Co-Founder, CTO
Researcher director, expert biochemistry, experienced in biotech
They support us
History and facts
Where are we ?
Discover Aceso, a biotech company committed to developing groundbreaking treatments with a profound impact on patients’ lives.
We offer a unique opportunity to join us on this exciting journey — to invest in and support a project.
If you would like to learn more about our vision, our science, and how you can be part of this meaningful adventure, we would be thrilled to hear from you.
Let’s create impact together.
ACESO THERAPEUTICS
6 B Boulevard Berthelot 34000 Montpellier
Welcome to contact us
for more details
contact@aceso-therapeutics.com